HypoxemiaMOXY-HSPNCT06169514
Health Systems and Policy Contexts of Medical Oxygen
An observational study of Hypoxemia and Morality, run by Murdoch Childrens Research Institute at 6 sites in 6 countries.
Trial summary
This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies. Read more about this study
- Who is it for?
- Ages 18 years and older
- How many people
- 1 participants
- Where
- 6 sitesin 6 countries
- Study dates
- 31 Jul 2024to Dec 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This study will be conducted in 6 of the 9 countries participating in the CHAI-led MOXY program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).
Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society.
Trial locations and contacts
6 sites in 6 countries. Contact the study team or a site near you to ask about taking part.
6 sites in 6 countries
Cambodia1 site, 1 recruiting
- Recruiting
Cambodia
Phnom Penh
Siyan Yi, PhD, siyan@nus.edu.sg
Liberia1 site, 1 recruiting
- Recruiting
Liberia
Monrovia
Readon Ideh, MD, rideh1010@gmail.com
Nigeria1 site, 1 recruiting
- Recruiting
Nigeria
Ibadan
Ayobami Bakare, MD, aadebayobakare@gmail.com
Rwanda1 site, 1 recruiting
- Recruiting
Rwanda
Kigali
Corneille Killy Ntihabose, MD, ckntihabose@gmail.com
Uganda1 site, 1 recruiting
- Recruiting
Uganda
Kampala
Freddy Kitutu, PhD, 256 705 79177, kitutufred@gmail.com
About this study
Official title: Understanding the Health Systems and Policy Contexts of Medical Oxygen in Africa and Asia (MOXY-HSP)
This is a mixed-methods program evaluation from a health systems and policy perspective, involving (i) stakeholder analysis, (ii) policy-implementation gap analysis, and (iii) comparative country case studies. This study aims to understand how national oxygen strategies achieve impact at national, and subnational level, across country contexts, at what cost.
The the investigators seek to:
Read more
- Involve policymakers, implementers (including private sector), and medical oxygen users in identifying challenges and understanding potential solutions to medical oxygen access;
- Generate new data on how medical oxygen systems work and can be improved from multiple perspectives;
- Draw lessons on medical oxygen that can directly inform national and global practice and policy.
This study will be conducted in 6 of the 9 countries participating in the Clinton Health Access Initiative (CHAI) led Medical Oxygen Implementation (MOXY) program (Uganda, Nigeria, Rwanda, Liberia, Lao PDR, Cambodia).
Key informants will be selected representing government, non-governmental agencies, professional associations, private sector, and civil society. This study will be completed over 4 years, with timelines varying between country study sites.
Read the detailed description
The investigators will use a concurrent mixed-methods design, with an overarching comparative case study methodology. The investigators will adopt an iterative approach, using co-design to adapt the study methodology to the specific context of each country and annual learning team meetings with stakeholders to refine the final case study topics (sub-study 3) and methodology.
Three embedded sub-studies are planned:
Sub-study 1 (Stakeholder Analysis) aims to understand the policy environment for medical oxygen services across different country contexts. This will be informed by the MOXY baseline survey, which includes data on oxygen-related facility readiness and clinical practices across the MOXY program areas. Data sources will include stakeholder interviews with participants from different levels (national, provincial, local) and policy perspectives (government, implementing/advising partners, practitioners, beneficiaries). Results will inform sub-study 2 and MOXY program implementation.
Sub-study 2 (Policy-Implementation Gap Analysis) aims to critically analyse the gap between policy intentions and actual implementation. This will be informed by the baseline facility readiness and clinical practice data. Data sources will include a desk review of oxygen-related policies, stakeholder in-depth interviews, and program administrative data. Results will inform implementation of country oxygen strategies and feed into prioritization of focus areas for sub-study 3.
Sub-study 3 (Comparative Country Case Studies) aims to compare oxygen programs across countries, focusing on particular challenges or unique solutions identified in sub-study 1 and 2. Data sources will include repeated desk review of oxygen-related policies and program administrative data, follow-up stakeholder interviews, and triangulation with quantitative survey results on facility readiness and clinical practices.
This research will also draw on national stakeholder dialogues - both to review, refine, and validate preliminary findings of the study team and to draw out feasible solutions/alternatives for both policy and practice and oxygen eco-system. In year 1 the investigators will generate key evidence about how the current strategies and polices are being translated into action, identifying key opportunities for implementing partners to focus support. Over years 2 and 3, the investigators will learn how these activities have affected medical oxygen service coverage, drawing lessons across country contexts and across different implementation approaches.
- Being tested
- No intervention
- Keywords
- Health system, Oxygen, Oxygen systems, Oxygen access, Pulse oximetry
- Medical subject headings
- Hypoxia, Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
No intervention
| Study group | Role | What they receive |
|---|---|---|
| Policy and stakeholder analysis across 6 countries | Policy and stakeholder analysis across 6 countries Receives: Other: No intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-depth stakeholder interviews on national medical oxygen strategies
In depth stakeholder interviews covering perspectives on policies, oversight, implementation, and related support towards the particular domain (e.g. measurement and indicators, health workforce capacity building, etc.)
Measured: 4 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2023
- Study start31 Jul 2024
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypoxemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 1 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Murdoch Childrens Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- University of Ibadan, University of Health Sciences, Lao People's Democratic Republic (PDR), University of Health Sciences, Cambodia, Makerere University, Ministry of Health, Liberia, Ministry of Health, Rwanda, Karolinska Institutet
- Responsible party
- Sponsor
- Investigators
- Hamish Graham, PhD, Principal investigator, Murdoch Childrens Research InstituteCarina King, PhD, Principal investigator, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06169514
- Sponsor's protocol ID
- HREC 100143
- Acronym
- MOXY-HSP
- Status last verified
- Nov 2025
- First submitted
- 29 Oct 2023
- Last updated
- 6 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No